Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359183 | 0.85 | ATM (0.59) | ATMTACR1CTSKCTSLCTSS | |
| SCHEMBL19134487 | 0.84 | ATM (0.58) | ATMTACR1SMN1; SMN2CTSKCTSL | |
| SCHEMBL17357789 | 0.81 | ATM (0.52) | ATMTACR1SMN1; SMN2MAPTSYK | |
| SCHEMBL17352430 | 0.79 | ATM (0.53) | ATMSMN1; SMN2SYKCTSKCTSL | |
| SCHEMBL6487029 | 0.79 | ATM (0.53) | ATMSMN1; SMN2SYKCTSKCTSL | |
| SCHEMBL23455705 | 0.79 | ATM (0.53) | ATMSMN1; SMN2SYKCTSKCTSL | |
| SCHEMBL23455707 | 0.79 | ATM (0.53) | ATMSMN1; SMN2SYKCTSKCTSL | |
| SCHEMBL23392518 | 0.78 | ATM (0.52) | ATMSYKCTSKCTSLCTSS | |
| SCHEMBL17351827 | 0.78 | ATM (0.52) | ATMSYKCTSKCTSLCTSS | |
| SCHEMBL15936982 | 0.78 | ATM (0.52) | ATMSYKCTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215767-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180179218-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-06-28 | — | — | US | disclosed |
| US-9828384-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828384-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| WO-2014120784-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179218-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ATM 2196/4885TACR1 41/4885SMN1; SMN2 913/4885 |
| US-20180215767-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ATM 2196/4885TACR1 41/4885SMN1; SMN2 913/4885 |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | ATM 2404/4885TACR1 137/4885SMN1; SMN2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.